<DOC>
	<DOCNO>NCT00377143</DOCNO>
	<brief_summary>Warfarin ( also call CoumadinÂ® ) anticoagulant drug ( blood thinner ) give patient help prevent blood clot form help prevent growth exist blood clot . The purpose study collect information possible method use determine best warfarin dose people start warfarin . This study focus find person 's stable dose well predict use new approach ( call `` pharmacogenetic-guided dosing '' ) compare current warfarin dose method . The pharmacogenetic-guided dosing method ( new warfarin dose method ) use person 's specific health genetic information calculate patient 's warfarin dose begin warfarin treatment . The hope research , may someday able use individual 's genetic information guide selection specific warfarin dose begin treatment , lead precise warfarin dose less need current trial error process .</brief_summary>
	<brief_title>PRospective Evaluation Comparing Initiation Warfarin StrategiEs ( PRECISE ) : Pharmacogenetic-guided Versus Usual Care</brief_title>
	<detailed_description>Warfarin mainstay therapy prevent venous thromboembolism ( VTE ) , pulmonary embolism ( PE ) , subsequent morbidity mortality . Despite proven efficacy reduce advent clot formation , patient-specific warfarin dose difficult predict , initial dose regimen often result supra- subtherapeutic anticoagulation , subsequently increase patient ' risk bleed embolism . It show interpatient warfarin dose variability due part genetic variation find cytochrome P450 2C9 metabolism pathway ( CYP2C9 ) , well proteins involve coagulation cascade , importantly vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) . A recent retrospective study show two gene addition several clinical/demographic factor account great 58 % variation patient-specific warfarin dos . However , study document prospective use information select initial warfarin dose . Hypothesis : Stable therapeutic management warfarin therapy precisely achieve patient prospectively dose base pharmacogenetic-guided dose equation compare usual care . Aim : To determine pharmacogenetic-guided dose warfarin superior usual care , define accuracy initial versus stable warfarin dose . This assessed mean absolute difference initial versus stable dose . Aim b : To determine stable warfarin dose quickly achieve use pharmacogenetic-guided dose equation compare usual care . This assessed time stable dose . Aim c : To determine pharmacogenetic-guided dose superior usual care term overdose underdosing patient . This assessed fraction population overdose fraction population underdosed two method . We propose evaluate pharmacogenetic-guided dose approach compare usual care initiation warfarin management . The select pharmacogenetic-guided equation validate equation include genetic clinical factor relatively easy incorporate current clinical practice . Patients newly initiate warfarin therapy hospital set randomize receive either pharmacogenetic-guided usual care , follow-up anticoagulation management service provide University Florida Health System Anticoagulation Clinic . Prospectively determine patient ' stable dose important clinical implication today 's management warfarin therapy . Being able predetermine patient 's stable dose upon initiation therapy potential decrease time spend supra- subtherapeutic anticoagulation reduce number clinic visit require achieve stable dose . Therefore propose study test use genotype data determine initial warfarin dose effective usual care predict stable dose . If document value approach , provide level evidence need translate pharmacogenetic-guided dosing warfarin clinical practice .</detailed_description>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Newly initiate warfarin Previous use warfarin Cancer Hepatic Disease History alcoholism Diarrheal illness Febrile Illness Blood dyscrasia Pregnancy Medical plan hold warfarin administration stable dose achieve ( ie . surgical intervention ) Dementia Active bleed Aneurysm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>warfarin</keyword>
	<keyword>pharmacogenomic</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>VKORC1</keyword>
	<keyword>polymorphism , single nucleotide</keyword>
</DOC>